Sabse acche Pharma & Healthcare funds
Defensive-growth exposure to pharma, hospitals and diagnostics.
Data updated · 18 direct-growth funds, 0–100 Smart Score se rank kiye hue
Neeche ki interactive table English mein hai — numbers aur fund names dono jagah same hain.
| ⚖ VS | Fund | Score ↓ | Verdict | 1Y | 3Y | 5Y | Sharpe | Sortino | Std Dev | Alpha | Beta | VR★ | P/E | Expense | AUM | Age |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBI Healthcare Opportunities SBI | 79 | Strong Buy | 21.3% | 24.7% | 18.3% | 1.26 | 2.02 | 14.4 | 5.3 | 0.83 | — | 55.6 | 1.02% | ₹5.4k Cr | 13.7y | |
| HDFC Pharma And Healthcare HDFC | 79 | Strong Buy | 26.9% | — | — | 1.82 | 2.61 | 14.0 | 21.0 | 0.66 | — | 49.8 | 1.11% | ₹2.9k Cr | 2.9y | |
| UTI Healthcare UTI | 68 | Buy | 18.3% | 25.1% | 16.2% | 1.16 | 1.98 | 16.0 | 4.6 | 0.90 | — | 42.6 | 1.28% | ₹1.4k Cr | 13.7y | |
| Kotak Healthcare Kotak | 64 | Buy | 27.2% | — | — | 1.16 | 1.64 | 14.4 | 14.6 | 0.68 | — | 50.4 | 1.09% | ₹676 Cr | 2.7y | |
| Mirae Asset Healthcare Mirae Asset | 59 | Hold | 20.3% | 23.4% | 15.4% | 1.09 | 1.71 | 16.2 | 3.0 | 0.94 | — | 47.9 | 0.61% | ₹3.4k Cr | 8.2y | |
| DSP Healthcare DSP | 58 | Hold | 17.9% | 22.5% | 15.4% | 1.10 | 1.78 | 14.9 | 4.3 | 0.79 | — | 35.4 | 0.71% | ₹3.6k Cr | 7.8y | |
| PGIM India Healthcare PGIM India | 51 | Hold | 24.7% | — | — | 0.55 | 0.75 | 13.1 | 10.4 | 0.66 | — | 56.6 | 0.92% | ₹112 Cr | 1.8y | |
| ICICI Pru Healthcare ICICI Pru | 49 | Hold | 9.2% | 23.2% | 15.9% | 1.08 | — | 16.2 | 3.4 | 0.91 | — | — | 1.33% | ₹6.8k Cr | 8.2y | |
| Bajaj Finserv Healthcare Bajaj Finserv | 47 | Hold | 22.0% | — | — | 0.39 | 0.53 | 13.4 | 6.5 | 0.68 | — | 52.8 | 0.88% | ₹377 Cr | 1.7y | |
| WhiteOak Capital Pharma And Heathcare WhiteOak | 46 | Hold | 22.0% | — | — | — | — | — | — | — | — | 51.3 | 1.16% | ₹825 Cr | 2.6y | |
| ABSL Pharma And Healthcare Aditya Birla Sun Life | 45 | Hold | 17.8% | 22.7% | 14.2% | 1.09 | 1.82 | 15.3 | 2.8 | 0.90 | — | 47.6 | 1.01% | ₹1.1k Cr | 7.2y | |
| Nippon India Pharma Nippon India | 41 | Avoid | 11.7% | 19.4% | 13.5% | 0.99 | 1.43 | 13.0 | 9.1 | 0.59 | — | 40.4 | 1.00% | ₹9.3k Cr | 13.7y | |
| ITI Pharma And Healthcare ITI | 39 | Avoid | 13.1% | 20.5% | — | 0.99 | 1.39 | 14.2 | 9.8 | 0.67 | — | 47.6 | 0.98% | ₹263 Cr | 4.8y | |
| LIC MF Healthcare LIC | 37 | Avoid | 17.1% | 23.4% | 12.5% | 1.11 | 1.72 | 15.9 | 4.0 | 0.88 | — | 52.3 | 1.42% | ₹98 Cr | 7.5y | |
| Baroda BNP Paribas Health And Wellness Baroda BNP Paribas | 37 | Avoid | 11.0% | — | — | 0.08 | 0.12 | 11.4 | 4.3 | 0.56 | — | 47.3 | 1.04% | ₹519 Cr | 1.2y | |
| Tata India Pharma & Healthcare Tata | 33 | Avoid | 10.1% | 20.7% | 14.6% | 0.93 | 1.53 | 16.4 | -0.0 | 0.98 | — | 44.7 | 0.97% | ₹1.5k Cr | 10.7y | |
| Quant Healthcare Quant | 23 | Avoid | 22.1% | 21.7% | — | 0.91 | 1.22 | 18.2 | 2.7 | 0.89 | — | 41.2 | 1.51% | ₹389 Cr | 3.2y | |
| Bandhan Healthcare Bandhan | 22 | Avoid | — | — | — | — | — | — | — | — | — | 43.0 | 1.20% | ₹319 Cr | 0.8y |
Pharma & Healthcare — Jhatpat jawaab
›Abhi sabse accha Pharma & Healthcare mutual fund kaun sa hai?
SBI Healthcare Opportunities abhi 18 Pharma & Healthcare funds mein #1 hai — FundLens Smart Score 79/100 (Strong Buy). 3 saal ka return 24.7%, 5 saal ka 18.3%, expense ratio 1.02% (direct plan). Ranking 07 Sept 2026 ke data se bani hai.
›Kis Pharma & Healthcare fund ka risk-adjusted return sabse accha hai?
Sortino ratio ke hisaab se HDFC Pharma And Healthcare category mein sabse aage hai — 2.61 (Sharpe 1.82). Matlab girawat ke har unit risk par sabse zyada return.
›Sabse kam expense ratio wala Pharma & Healthcare fund kaun sa hai?
Mirae Asset Healthcare — saalana 0.61% (direct plan), category mein sabse kam. Kam fees lambe samay mein aapke favour mein compound hoti hai.
›AUM ke hisaab se sabse chhota Pharma & Healthcare fund kaun sa hai?
LIC MF Healthcare — ₹98 Cr, category mein sabse chhota. Chhote funds phurteele ho sakte hain, par size ko akeli khoobi mat maano.
›Pharma & Healthcare fund mein kitne samay ke liye invested rehna chahiye?
Pharma & Healthcare funds ka risk bahut ooncha hota hai, isliye aam taur par 7+ saal ka nazariya samajhdaari hai. Defensive-growth exposure to pharma, hospitals and diagnostics. Yeh research hai, investment advice nahi.
Yahi jawaab chat mein chahiye? FundLens se poochho